Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dissecting the Role of miR-3916 and miR3613-5p in Breast Cancer and Developing a Metastases Predictor PORTENT Algorithm

NCT07372261 is registered in ClinicalTrials.gov with Casa Sollievo della Sofferenza IRCCS as lead sponsor.

NCT NCT07372261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07372261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dissecting the Role of miR-3916 and miR3613-5p in Breast Cancer and Developing a Metastases Predictor PORTENT Algorithm
Lead sponsor
Casa Sollievo della Sofferenza IRCCS
Phase
Observational
Overall status
Enrolling by invitation
Start date
March 10, 2022
Completion date
December 31, 2026
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer early stage breast cancer (stage 1-3)